Science

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Michael Duruisseaux/X

Feb 9, 2025, 15:33

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Michael Duruisseaux, Physician-Scientist in the Onco-Pharmacology team at the Lyon Cancer Research Center, shared an article by Alison M. Schram, et al. on X:

“Hot of the press NEJM: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer | New England Journal of Medicine.

First effective targeted therapy in NRG1-fusion + solid tumors.

Very proud to collaborate to this study.”

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer.

Authors: Alison M. Schram, et al.

Michael Duruisseaux: First effective targeted therapy in NRG1-fusion + solid tumors

Alison M. Schram cancer fight against cancer Global fight against cancer Lyon Cancer Research Center Michael Duruisseaux NEJM New England Journal of Medicine NRG1 fusion OncoDaily Oncology OncoPharmacology solid tumors zenocutuzumab

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer